Show simple item record

dc.contributor.authorVergel León, Ana Maríaspa
dc.date.accessioned2020-06-26T19:58:05Z
dc.date.available2020-06-26T19:58:05Z
dc.date.issued2015
dc.identifier.urihttp://hdl.handle.net/20.500.12749/1708
dc.description.abstractLas dislipidemia son trastornos caracterizados por un aumento de los niveles de colesterol y/o triglicérido con una prevalencia en nuestra población entre un 40-50% en la población > 50 años, lo cual aumenta el riesgo de esta población para presentar enfermedad coronaria. Se conoce actualmente que los principales factores de riesgo para ateroesclerosis son: elevación sérica de colesterol-LDL y triglicéridos, hipertensión arterial, tabaquismo, diabetes mellitus, insuficiencia renal crónica, síndrome metabólico, historia familiar positiva de enfermedad cardiovascular y aumento de mediadores inflamatorios como Apo B entre otros . 1 Dada la elevada prevalencia de alteraciones en el perfil lipídico se construyeron las guías del Programa Nacional sobre Educación en Colesterol- Panel para el Tratamiento en Adultos (NCEP – ATP III) apartir de las cuales se busca tener un impacto en las cifras de metas de perfil metabólico para disminuir el riesgo de presentar eventos cardiovasculares y en caso de paciente que ya padecieron eventos cardiovasulares disminuir su re-incidencia. 2 Las obesidad y las alteraciones metabólicas del perfil lipídico se han convertido en un problema de salud pública creciente, en virtud de la elevada incidencia de enfermedad cardiovascular secundaria de las dislipidemias a nivel mundial, y es por esto que las medidas de prevención, detección y tratamiento oportuno de los factores de riesgo modificables para su desarrollo son de crucial importancia.,3,4 El estudio Múltiple Risk Factor Intervention Trial (MRFIT) demostró una relación continua y gradual entre los niveles séricos de colesterol y la mortalidad total por cardiopatía isquémica. Es por esto que en el presente estudio se evaluo el nivel de cumplimiento de las metas terapéuticas del perfil lipidico. Y de esta manera describir la respuesta a cada uno de los esquemas de tratamiento y la adherencia del paciente.spa
dc.description.tableofcontents1. INTRODUCCION 5 2. PROBLEMA Y JUSTIFICACION 6 3. MARCO TEORICO 7 4. OBJETIVOS 9 5. DISEÑO Y CONDUCCION DEL ESTUDIO - Diseño del estudio 10 - Criterios de inclusión y de exclusión 10 - Universo y muestra 10 6. ANÁLISIS ESTADÍSTICO -Plan de análisis 11 - Calculo y tamaño de la muestra 11 7. VARIABLES 12 8. INTERVENCION QUE SE REALIZO 13 9. CONSIDERACIONES ETICAS 14 10. RESULTADOS 15 11. DISCUSIÓN 18 12. CONCLUSIONES 20 13. DECLARACION DE CONFLICTO DE INTERESES 21 14. BIBLIOGRAFIA 22spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.title¿Cuál el grado de cumplimiento de las metas perfil metabólicas de acuerdo a la guía de NCEP - ATP III en pacientes con enfermedad coronaria en una institución hospitalaria?spa
dc.title.translatedWhat is the degree of compliance with the metabolic profile goals according to the NCEP - ATP III guideline in patients with coronary artery disease in a hospital institution?eng
dc.degree.nameEspecialista en Epidemiologíaspa
dc.coverageBucaramanga (Santander, Colombia)spa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Epidemiologíaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsCoronary heart diseaseeng
dc.subject.keywordsMetabolismeng
dc.subject.keywordsRegulation of metabolismeng
dc.subject.keywordsCoronary artery diseaseeng
dc.subject.keywordsMedicineeng
dc.subject.keywordsEpidemiologyeng
dc.subject.keywordsInvestigationseng
dc.subject.keywordsControleng
dc.subject.keywordsPatientseng
dc.subject.keywordsCoronary heart diseaseeng
dc.subject.keywordsHospital institutioneng
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.relation.referencesVergel León, Ana María (2015). Cuál el grado de cumplimiento de las metas perfil metabólicas de acuerdo a la guía de NCEP - ATP III en pacientes con enfermedad coronaria en una institución hospitalaria. Bucaramanga (Colombia) : Universidad Autónoma de Bucaramanga UNABspa
dc.relation.referencesCholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-78. Disponible en: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61350-5/abstractspa
dc.relation.referencesStamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA,1986;256(20):2823-2828.spa
dc.relation.referencesStamler J, Daviglus ML, Garside DB, et al. Low-risk cardiovascular status: impact on cardiovascular mortality and longevity. Pediatric Prevention of Atherosclerotic Cardiovascular Disease. London, England: Oxford University Press, 2006:49-60.spa
dc.relation.referencesExpert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497. 
Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=193847spa
dc.relation.referencesMerchán VA, Ruiz MA, Ashner MP, et al. Segundo consenso nacional sobre la detección, evaluación y tratamiento de las dislipoproteinemias en adultos. Rev Colomb Cardiol 2005; 11: (Supl. 2): 405-490.spa
dc.relation.referencesCannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol, 2006; 48: 438-445. Disponible en: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0023097/spa
dc.relation.referencesSmith SC, Allen J, Blair SN, et al. Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation, 2006; 113: 2363-2372. Disponible: http://circ.ahajournals.org/content/113/19/2363.fullspa
dc.relation.referencesCommittee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine; Editores: Graham E, Mancher M, Wolman DM, Greenfield S, Steinberg E. Clinical Practice Guidelines We Can Trust: The National Academies Press, 2011. Disponible: http://www.ncbi.nlm.nih.gov/books/NBK209539/?report=readerspa
dc.relation.referencesGibbons GH, Harold JG, Jessup M, Robertson RM, Oetgen WJ. Next Steps in Developping Clinical Practice Guidelines for Prevention. J Am Coll Cardiol, 2013. 62(15):1399-400. Disponible en: http://www.sciencedirect.com/science/article/pii/S0735109713030982spa
dc.relation.referencesHicks RC, Golledge J, Mir-Hasseine R, Powell JT. Vasoative effects of fibrinogen on saphenous vein. Nature ,1996;379:818-20.spa
dc.relation.referencesRabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherotrombotic plaque. Atherosclerosis, 1994; 105: 1-7.spa
dc.relation.referencesSchneider DJ, Taaties DJ, Howard DB, Sobel BE. Increased reactivity of platelets induced by fibrinogen independent of cardiovascular risk. J Am Coll Cardiol, 1999; 33:261-6.spa
dc.relation.referencesLibby P. Current concepts of the pathgenesis of acute coronary syndromes. Circulation, 2001; 104:365-72.spa
dc.relation.referencesMosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005; 3 (8): 1894-904.spa
dc.relation.referencesKoeing W.Fibrinogen in cardiovascular disease: an update. Thromb Haemost, 2003; 89: 601-9.spa
dc.subject.lembEnfermedad coronariaspa
dc.subject.lembMetabolismospa
dc.subject.lembRegulación del metabolismospa
dc.subject.lembCoronariopatíaspa
dc.subject.lembMedicinaspa
dc.subject.lembEpidemiologíaspa
dc.subject.lembInvestigacionesspa
dc.subject.lembControlspa
dc.description.abstractenglishDyslipidemia are disorders characterized by an increase in cholesterol and / or triglyceride levels with a prevalence in our population between 40-50% in the population> 50 years, which increases the risk of this population to present coronary disease. It is currently known that the main risk factors for atherosclerosis are: elevated serum LDL-cholesterol and triglycerides, arterial hypertension, smoking, diabetes mellitus, chronic renal failure, metabolic syndrome, positive family history of cardiovascular disease and increased inflammatory mediators such as Apo B among others. one Given the high prevalence of alterations in the lipid profile, the guidelines of the National Program on Cholesterol Education-Panel for Treatment in Adults (NCEP - ATP III) were constructed, from which it is sought to have an impact on the figures of profile goals metabolic to reduce the risk of presenting cardiovascular events and in the case of patients who already suffered cardiovascular events, reduce their re-incidence. two Obesity and metabolic alterations of the lipid profile have become a growing public health problem, due to the high incidence of secondary cardiovascular disease of dyslipidemias worldwide, and that is why prevention, detection and treatment measures Timely modifiable risk factors for their development are of crucial importance., 3,4 The Multiple Risk Factor Intervention Trial (MRFIT) study demonstrated a continuous and gradual relationship between serum cholesterol levels and total mortality from ischemic heart disease. This is why in the present study the level of compliance with the therapeutic goals of the lipid profile was evaluated. And in this way describe the response to each of the treatment schemes and patient adherence.eng
dc.subject.proposalPacientespa
dc.subject.proposalEnfermedad coronariaspa
dc.subject.proposalInstitución hospitalariaspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.contributor.researchgroupGrupo de Investigaciones Clínicasspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 2.5 Colombia